CANF Valuation

Can Fite Biopharma Ltd

Add to Watchlist

Advanced Chart

0.631

-0.032(-4.823%)1D

Overview
Forecast
Valuation
Earnings

CANF Relative Valuation

CANF's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CANF is overvalued; if below, it's undervalued.

Historical Valuation

Can Fite Biopharma Ltd (CANF) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -0.75. The fair price of Can Fite Biopharma Ltd (CANF) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 0.65 USD , Can Fite Biopharma Ltd is Undervalued By Fair.

Relative Value

Fair Zone

+Inf-+Inf

Current Price：0.65

Fair

Undervalued

-1.28

Trailing

Forward

0.08

EV/EBITDA

Can Fite Biopharma Ltd. (CANF) has a current EV/EBITDA of 0.08. The 5-year average EV/EBITDA is 0.22. The thresholds are as follows: Strongly Undervalued below -1.00, Undervalued between -1.00 and -0.39, Fairly Valued between 0.83 and -0.39, Overvalued between 0.83 and 1.44, and Strongly Overvalued above 1.44. The current Forward EV/EBITDA of 0.08 falls within the Historic Trend Line -Fairly Valued range.

-0.51

EV/EBIT

Can Fite Biopharma Ltd. (CANF) has a current EV/EBIT of -0.51. The 5-year average EV/EBIT is -1.06. The thresholds are as follows: Strongly Undervalued below -3.39, Undervalued between -3.39 and -2.22, Fairly Valued between 0.11 and -2.22, Overvalued between 0.11 and 1.27, and Strongly Overvalued above 1.27. The current Forward EV/EBIT of -0.51 falls within the Historic Trend Line -Fairly Valued range.

0.00

Can Fite Biopharma Ltd. (CANF) has a current PS of 0.00. The 5-year average PS is 15.62. The thresholds are as follows: Strongly Undervalued below -13.94, Undervalued between -13.94 and 0.84, Fairly Valued between 30.40 and 0.84, Overvalued between 30.40 and 45.18, and Strongly Overvalued above 45.18. The current Forward PS of 0.00 falls within the Undervalued range.

0.63

P/OCF

Can Fite Biopharma Ltd. (CANF) has a current P/OCF of 0.63. The 5-year average P/OCF is -1.24. The thresholds are as follows: Strongly Undervalued below -6.18, Undervalued between -6.18 and -3.71, Fairly Valued between 1.22 and -3.71, Overvalued between 1.22 and 3.69, and Strongly Overvalued above 3.69. The current Forward P/OCF of 0.63 falls within the Historic Trend Line -Fairly Valued range.

0.64

P/FCF

Can Fite Biopharma Ltd. (CANF) has a current P/FCF of 0.64. The 5-year average P/FCF is -0.44. The thresholds are as follows: Strongly Undervalued below -4.24, Undervalued between -4.24 and -2.34, Fairly Valued between 1.46 and -2.34, Overvalued between 1.46 and 3.35, and Strongly Overvalued above 3.35. The current Forward P/FCF of 0.64 falls within the Historic Trend Line -Fairly Valued range.

Can Fite Biopharma Ltd (CANF) has a current Price-to-Book (P/B) ratio of 364.16. Compared to its 3-year average P/B ratio of 254.41 , the current P/B ratio is approximately 43.14% higher. Relative to its 5-year average P/B ratio of 154.22, the current P/B ratio is about 136.12% higher. Can Fite Biopharma Ltd (CANF) has a Forward Free Cash Flow (FCF) yield of approximately -58.22%. Compared to its 3-year average FCF yield of -43.80%, the current FCF yield is approximately 32.93% lower. Relative to its 5-year average FCF yield of -32.97% , the current FCF yield is about 76.58% lower.

364.16

P/B

Median3y

254.41

Median5y

154.22

-58.22

FCF Yield

Median3y

-43.80

Median5y

-32.97

Competitors Valuation Multiple

The average P/S ratio for CANF's competitors is 1.38, providing a benchmark for relative valuation. Can Fite Biopharma Ltd Corp (CANF) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of -21.32%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

CANF.A

Can Fite Biopharma Ltd

Barinthus Biotherapeutics PLC

Loss

48.04M

TELO.O

Telomir Pharmaceuticals Inc

Loss

47.78M

PSTV.O

Plus Therapeutics Inc

Performance Decomposition

Market capitalization of CANF increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of CANF in the past 1 year is driven by Unknown.